วัคซีนป้องกันมะเร็งปากมดลูก: สถานการณ์ปัจจุบันและบทบาทพยาบาล
คำสำคัญ:
วัคซีนป้องกันมะเร็งปากมดลูก, วัคซีนเอชพีวี, มะเร็งปากมดลูกบทคัดย่อ
มะเร็งปากมดลูกเป็นมะเร็งที่พบบ่อยในสตรีไทย สาเหตุส่วนใหญ่เกิดจากเชื้อไวรัสเอชพีวี ซึ่งในปัจจุบันมีวัคซีนป้องกันไวรัสเอชพีวีแล้ว สถานการณ์การให้วัคซีนเอชพีวีในประเทศไทยพบว่า การเข้าถึงวัคซีนเอชพีวียังไม่ครอบคลุมกลุ่มเป้าหมาย บุคลากรพยาบาลมีความรู้เรื่องวัคซีนเอชพีวี ในระดับปานกลาง ผู้รับบริการยังมีความรู้ความเข้าใจไม่เพียงพอต่อการรับวัคซีนเอชพีวี ดังนั้นพยาบาลจึงควรมีบทบาทในการส่งเสริมความสำเร็จของการรับวัคซีนเอชพีวีดังนี้ 1) การจัดอบรมฟื้นฟูความรู้สำหรับพยาบาลเกี่ยวกับการติดเชื้อไวรัสเอชพีวีและวัคซีนป้องกันมะเร็งปากมดลูกให้ทันสมัย 2) การให้ความรู้ความเข้าใจที่ถูกต้องสำหรับเด็ก วัยรุ่น และผู้ปกครอง เกี่ยวกับมะเร็งปากมดลูก ประโยชน์ของวัคซีนเอชพีวี วิธีการการฉีดวัคซีน ตลอดจนข้อจำกัดของวัคซีนเอชพีวี 3) การให้บริการเชิงรุกเพื่อให้การป้องกันมะเร็งปากมดลูกและการฉีดวัคซีนเอชพีวี 4) การพัฒนางานวิจัยที่เกี่ยวข้องกับปัญหาและอุปสรรคของการได้รับวัคซีนเอชพีวี
เอกสารอ้างอิง
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al., editors. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Lyon, France: International Agency for Research on Cancer (IARC); 2012.
2. Strategy and Planning Division, Office of the Permanent Secretary. Public Health Statistics A.D.2018. Nonthaburi: Ministry of Public Health; 2018.
3. World Health Organization. Human Papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec 2009;84(15):118-31.
4. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, et al. Human papillomavirus and related diseases report in Thailand. Summary Report. n.p.: ICO Information Centre on HPV and Cancer (HPV Information Centre); 2017.
5. Srisomboon J, Termrungruanglert W. HPV Vaccine. In: Srisomboon J, Kietpeerakool C., editors. Gynecologic Oncology. Bangkok: RTCOG; 2010. p. 33-46 (in Thai)
6. Galani E, Christodoulou C. Human papilloma viruses and cancer in the post-vaccine era. Clin Microbiol Infect 2009;15(11):977-81.
7. Hutchison DJ, Klein KC. Human papillomavirus disease and vaccines. Am J Health Syst Pharm 2008;65(22):2105-12.
8. ACOG Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin No.109: Cervical cytology screening. Obstet Gynecol 2009;114(6):1409-20.
9. Dawar M, Deeks S, Dobson S. Human papillomavirus vaccines launch a new era in cervical cancer prevention. CMAJ 2007;177(5):456-61.
10. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121(3):621-32.
11. World Health Organization. HPV infection and cervical cancer [Internet]. 2016 [Cited 2017 Dec 17]. Available from: http://apps.who.int/iris/bitstream/10665/253123/1/9789241549769-eng.pdf?ua=1.
12. Viens LJ, Henley SJ, Watson M, Markowitz LE, Thomas CC, Thompson TD, et al. Human Papillomavirus-Associated Cancers-United States, 2008–2012. MMWR Morb Mortal Wkly Rep 2016;65(26):661-6.
13. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009;124(7):1626-36.
14. Ault KA. Human papillomavirus vaccines: an update for gynecologists. Clin Obstet Gynecol 2008;51(3):527-32.
15. Hakim AA, Dinh TA. Worldwide impact of the human papillomavirus vaccine. Curr Treat Options Oncol 2009;10(1-2):44-53.
16. World Health Organization. Human papillomavirus vaccines: WHO position paper. Wkly Epidemiol Rec 2014;43(89):465-92.
17. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63(RR-05):1-30.
18. Petrosky E, Bocchini JA Jr, Hariri S, Chesson H, Curtis R, Saraiya M, et al. Use of 9-valent Human Papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015;64(11):300-4.
19. Kash N, Lee MA, Kollipara R, Downing C, Guidry J, Tyring SK. Safety and efficacy data on vaccines and immunization to human papillomavirus. J Clin Med 2015;4(4):614-33.
20. Chichareon S, Herrero R, Munoz N, Bosch FX, Jacobs MV, Deacon J, et al. Risk factors for cervical cancer in Thailand: a case-control study. J Natl Cancer Inst 1998;90(1):50-7.
21. Hakim AA, Lin PS, Wilczynski S, Nquyen K, Lynes B, Wakabayashi MT. Indications and efficacy of the human papillomavirus vaccine. Curr Treat Options Oncol 2007;8(6):393-401.
22. Termrungruang W, Kasemsarn P, Srisomboon J. HPV-related diseases and HPV vaccines. HPV newsletter. Bangkok: Rakluke Publishing Service; 2010. (in Thai)
23. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009;339:b3884. doi: 10.1136/bmj.b3884
24. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination-updated recommendations of the advisory committee on immunization practices. MMWR 2016;65(49):1405-8.
25. World Health Organization. WHO recommendations for HPV vaccination [Internet]. 2016 [cited 2017 Dec 17]. Available from: http://apps.who.int/iris/bitstream/10665/253123/1/9789241549769-eng.pdf?ua=1.
26. Talungchit P. Accessibility to Reproductive Health Care Service of Adolescents. In: Tanmahasamut P, Chanprapaph P, Jaishuen A, Wongwananuruk T, Lertbunnaphong T, editors. OB-GYN in practice 2014. Bangkok: Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital Mahidol University; 2014. p. 1-6. (in Thai)
27. Songthap A, Pitisuttithum P, Kaewkungwal J, Fungladda W, Bussaratid V, Koonsaeng S. Knowledge, attitudes, and acceptability of a human papillomavirus vaccine among healthcare providers. Southeast Asian J Trop Med Public Health 2009;40(5):1048-56.
28. World Health Organization. Implementation-training, service delivery and supervision [Internet]. 2016 [cited 2017 Dec 17]. Available from: http://apps.who.int/iris/bitstream/10665/253123/1/9789241549769-eng.pdf?ua=1.
29. World Health Organization. Developing a communication plan [Internet]. 2016 [cited 2017 Dec 17]. Available from: http://apps.who.int/iris/bitstream/10665/253123/1/9789241549769-eng.pdf?ua=1.
30. Gerend MA, Lee SC, Shepherd JE. Predictors of human papillomavirus vaccination acceptability among underserved women. Sex Transm Dis 2007;34(7):468-71.
2. Strategy and Planning Division, Office of the Permanent Secretary. Public Health Statistics A.D.2018. Nonthaburi: Ministry of Public Health; 2018.
3. World Health Organization. Human Papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec 2009;84(15):118-31.
4. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, et al. Human papillomavirus and related diseases report in Thailand. Summary Report. n.p.: ICO Information Centre on HPV and Cancer (HPV Information Centre); 2017.
5. Srisomboon J, Termrungruanglert W. HPV Vaccine. In: Srisomboon J, Kietpeerakool C., editors. Gynecologic Oncology. Bangkok: RTCOG; 2010. p. 33-46 (in Thai)
6. Galani E, Christodoulou C. Human papilloma viruses and cancer in the post-vaccine era. Clin Microbiol Infect 2009;15(11):977-81.
7. Hutchison DJ, Klein KC. Human papillomavirus disease and vaccines. Am J Health Syst Pharm 2008;65(22):2105-12.
8. ACOG Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin No.109: Cervical cytology screening. Obstet Gynecol 2009;114(6):1409-20.
9. Dawar M, Deeks S, Dobson S. Human papillomavirus vaccines launch a new era in cervical cancer prevention. CMAJ 2007;177(5):456-61.
10. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121(3):621-32.
11. World Health Organization. HPV infection and cervical cancer [Internet]. 2016 [Cited 2017 Dec 17]. Available from: http://apps.who.int/iris/bitstream/10665/253123/1/9789241549769-eng.pdf?ua=1.
12. Viens LJ, Henley SJ, Watson M, Markowitz LE, Thomas CC, Thompson TD, et al. Human Papillomavirus-Associated Cancers-United States, 2008–2012. MMWR Morb Mortal Wkly Rep 2016;65(26):661-6.
13. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009;124(7):1626-36.
14. Ault KA. Human papillomavirus vaccines: an update for gynecologists. Clin Obstet Gynecol 2008;51(3):527-32.
15. Hakim AA, Dinh TA. Worldwide impact of the human papillomavirus vaccine. Curr Treat Options Oncol 2009;10(1-2):44-53.
16. World Health Organization. Human papillomavirus vaccines: WHO position paper. Wkly Epidemiol Rec 2014;43(89):465-92.
17. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63(RR-05):1-30.
18. Petrosky E, Bocchini JA Jr, Hariri S, Chesson H, Curtis R, Saraiya M, et al. Use of 9-valent Human Papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015;64(11):300-4.
19. Kash N, Lee MA, Kollipara R, Downing C, Guidry J, Tyring SK. Safety and efficacy data on vaccines and immunization to human papillomavirus. J Clin Med 2015;4(4):614-33.
20. Chichareon S, Herrero R, Munoz N, Bosch FX, Jacobs MV, Deacon J, et al. Risk factors for cervical cancer in Thailand: a case-control study. J Natl Cancer Inst 1998;90(1):50-7.
21. Hakim AA, Lin PS, Wilczynski S, Nquyen K, Lynes B, Wakabayashi MT. Indications and efficacy of the human papillomavirus vaccine. Curr Treat Options Oncol 2007;8(6):393-401.
22. Termrungruang W, Kasemsarn P, Srisomboon J. HPV-related diseases and HPV vaccines. HPV newsletter. Bangkok: Rakluke Publishing Service; 2010. (in Thai)
23. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009;339:b3884. doi: 10.1136/bmj.b3884
24. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination-updated recommendations of the advisory committee on immunization practices. MMWR 2016;65(49):1405-8.
25. World Health Organization. WHO recommendations for HPV vaccination [Internet]. 2016 [cited 2017 Dec 17]. Available from: http://apps.who.int/iris/bitstream/10665/253123/1/9789241549769-eng.pdf?ua=1.
26. Talungchit P. Accessibility to Reproductive Health Care Service of Adolescents. In: Tanmahasamut P, Chanprapaph P, Jaishuen A, Wongwananuruk T, Lertbunnaphong T, editors. OB-GYN in practice 2014. Bangkok: Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital Mahidol University; 2014. p. 1-6. (in Thai)
27. Songthap A, Pitisuttithum P, Kaewkungwal J, Fungladda W, Bussaratid V, Koonsaeng S. Knowledge, attitudes, and acceptability of a human papillomavirus vaccine among healthcare providers. Southeast Asian J Trop Med Public Health 2009;40(5):1048-56.
28. World Health Organization. Implementation-training, service delivery and supervision [Internet]. 2016 [cited 2017 Dec 17]. Available from: http://apps.who.int/iris/bitstream/10665/253123/1/9789241549769-eng.pdf?ua=1.
29. World Health Organization. Developing a communication plan [Internet]. 2016 [cited 2017 Dec 17]. Available from: http://apps.who.int/iris/bitstream/10665/253123/1/9789241549769-eng.pdf?ua=1.
30. Gerend MA, Lee SC, Shepherd JE. Predictors of human papillomavirus vaccination acceptability among underserved women. Sex Transm Dis 2007;34(7):468-71.
ดาวน์โหลด
เผยแพร่แล้ว
2020-08-03
ฉบับ
ประเภทบทความ
บทความวิชาการ
สัญญาอนุญาต
เนื้อหาบทความหรือข้อคิดเห็นต่างๆ ในวารสารพยาบาลสภากาชาดไทยนี้ เป็นความคิดเห็นของผู้เขียนบทความ ไม่ใช่ความเห็นของกองบรรณาธิการ หรือสถาบันการพยาบาลศรีสวรินทิรา สภากาชาดไทย
